codevelopment agreement
Illumina, Kartos Therapeutics Partner to Develop TP53 Companion Diagnostic
The two companies will codevelop the next-generation sequencing test for Kartos's MDM2 inhibitor, KRT-232, being studied in TP53 wild-type blood cancers.
The new partners seek to close the information loop by including providers, payors, and patients in biomarker-guided cancer therapy decisions.
Qiagen, Inovio Expand CDx Partnership, Starting With NGS Test for Cervical Dysplasia Therapy
The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
UK Startup Gabriel Precision Oncology Leans on Congenica to Broaden NGS Use in Cancer Testing
Premium
Spun out of the Glasgow Precision Oncology Laboratory, Gabriel wants targeted sequencing to become the norm for all somatic cancer patients.
Agendia, Paige Partner to Codevelop New Assays Using MammaPrint, BluePrint Signatures
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
Sep 11, 2019